BioLineRx (NASDAQ:BLRX) Posts Earnings Results, Beats Expectations By $0.07 EPS

BioLineRx (NASDAQ:BLRX) issued its earnings results on Thursday. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07, Zacks reports. The company had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $0.17 million. During the same period in the prior year, the firm posted ($0.09) earnings per share.

BioLineRx Price Performance

Shares of NASDAQ BLRX opened at $1.12 on Friday. The firm has a market cap of $81.13 million, a P/E ratio of -1.24 and a beta of 1.40. The business’s 50 day moving average price is $1.20 and its 200 day moving average price is $1.46. BioLineRx has a 52 week low of $0.81 and a 52 week high of $2.53. The company has a quick ratio of 1.86, a current ratio of 1.53 and a debt-to-equity ratio of 0.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its holdings in BioLineRx by 49.1% during the 3rd quarter. Renaissance Technologies LLC now owns 68,222 shares of the biotechnology company’s stock worth $63,000 after buying an additional 22,478 shares during the last quarter. LPL Financial LLC lifted its holdings in BioLineRx by 152.7% during the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after buying an additional 71,134 shares during the last quarter. Envestnet Asset Management Inc. purchased a new stake in BioLineRx during the 1st quarter worth about $88,000. Finally, Atria Wealth Solutions Inc. purchased a new stake in BioLineRx in the first quarter valued at $178,000. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BLRX. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of BioLineRx in a report on Tuesday. StockNews.com upgraded BioLineRx to a “sell” rating in a report on Wednesday.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.